ESOREST Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

CENTAUR PHARMACEUTICALS PVT. LTD., India

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. ESOREST 20:

    Esomeprazole 20mg

    2. ESOREST 40:

    Esomeprazole 40mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    For GERD including:

    - Symptomatic treatment of GERD

    - Erosive reflux esophagitis

    - Long-term management of patients with healed esophagitis

    - The eradication of H.pylori in combination with appropriate antibiotics

    - H.pylori-associated duodenal ulcer

    Dosage and Administrations

    Treatment of erosive esophagitis: 40mg once daily for 4-8weeks.

    Symptomatic GERD/Maintenance of erosive esophagitis: 20mg once daily for 4 weeks.

    H.pylori: 40mg once daily for 10 days in combination with appropriate antibiotics.

    ESOREST should be taken at least 1 hour before meals.

  • ហាមប្រើ

    In patients with previous hypersensitivity reactions to Esomeprazole, a component of the product formulation or to substituted benzimidazoles.

  • ផលរំខាន

    The adverse events associated with ESOREST therapy are similar to those seen with placebo or omeprazole therapy and similar to other PPIs available.

    The most common adverse events reported in clinical trials were: diarrhea, abdominal pain, flatulence, gastritis, nausea and headache.

  • អន្តរប្រតិកម្ម

    - Changes in gastric pH can affect bioavailability of certain medications. (e.g. Ketoconazole, iron salts)

    - ESOREST can decrease the clearance of Diazepam by 45% and increase the plasma levels of Diazepam.

    - No drug-drug interaction found between Esomeprazole, phenytoin, r-warfarin, quinidine, amoxicillin and clarithromycin.

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    Pregnancy

    There are no adequate and well-controlled studies in pregnant women. Sporadic reports have been received of congenital abnormalities occurring in infants born to women who have received omeprazole during pregnancy.

    Omeprazole is classified as Pregnancy Category C. The manufacturer recommends that Omeprazole be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Esomeprazole an enantiomer of Omeprazole is classified as Pregnancy Category B.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    Symptomatic response to therapy with ESOREST does not preclude the presence of gastric malignancy.

    Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with Omeprazole, of which Esomeprazole magnesium is an enantiomer.

  • សកម្មភាពឱសថ

    Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ in the gastric parietal cell. Esomeprazole is the first single isomer PPI developed for the treatment of acid- related diseases.

    The S- and R- isomers are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, ESOREST blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20-40mg and leads to inhibition of gastric acid secretion.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp